Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists.
Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists. Cancer Lett. 2010 Jul 28; 293(2):240-53.